Legis Daily

Maintaining Investments in New Innovation Act

USA118th CongressS-476| Senate 
| Updated: 2/16/2023
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (3)
Marsha Blackburn (Republican)Steve Daines (Republican)Ted Budd (Republican)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 16, 2023
Introduced in Senate
Feb 16, 2023
Read twice and referred to the Committee on Finance.
Dec 17, 2024

Latest Companion Bill Action

HR 118-5547
Referred to the Subcommittee on Health.
  • February 16, 2023
    Introduced in Senate


  • February 16, 2023
    Read twice and referred to the Committee on Finance.


  • December 17, 2024

    Latest Companion Bill Action

    HR 118-5547
    Referred to the Subcommittee on Health.

Health

Related Bills

  • HR 118-5547: Maintaining Investments in New Innovation Act
GeneticsMedicarePrescription drugs

Maintaining Investments in New Innovation Act

USA118th CongressS-476| Senate 
| Updated: 2/16/2023
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 16, 2023
Introduced in Senate
Feb 16, 2023
Read twice and referred to the Committee on Finance.
Dec 17, 2024

Latest Companion Bill Action

HR 118-5547
Referred to the Subcommittee on Health.
  • February 16, 2023
    Introduced in Senate


  • February 16, 2023
    Read twice and referred to the Committee on Finance.


  • December 17, 2024

    Latest Companion Bill Action

    HR 118-5547
    Referred to the Subcommittee on Health.
Robert Menendez

Robert Menendez

Democratic Senator

New Jersey

Cosponsors (3)
Marsha Blackburn (Republican)Steve Daines (Republican)Ted Budd (Republican)

Finance Committee

Health

Related Bills

  • HR 118-5547: Maintaining Investments in New Innovation Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
GeneticsMedicarePrescription drugs